Oxurion NV — Major Shareholding Notification 2025

Jun 30, 2025

Oxurion Receives Transparency Notification from Atlas Special Opportunities II LLC

Leuven, BELGIUM – June 30, 2025 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation¹ it has received a transparency notification as follows:

Oxurion received a transparency notification on June 26, 2025, from Atlas Special Opportunities II, LLC indicating that as of June 26, 2025, it held 621,773 shares of the then outstanding 8,496,303 shares, and therefore crossed under the threshold (10%) by virtue of the selling of voting securities.

About Oxurion

Oxurion NV (Euronext Brussels: OXUR) is a biopharmaceutical group in transition, combining therapeutic innovation with technologies applied to clinical research. Through its rapidly expanding technology division, Oxurion is building integrated expertise around clinical data, with the ambition to accelerate, secure, and transform the processes involved in developing new treatments. The Group's headquarters are based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forwardlooking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV Pascal Ghoson Chief Executive Officer Pascal.ghoson@oxurion.com

________

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

FSMA MARKETS AUTHORITY	FINANCIAL SERVICES AND		Form TR-1 BE PART I	Transparency notification
1) Status of the notification
	Final
2) Issuer
Identification number 0881-620-924	Name OXURION
3) Reason for the notification
	Acquisition or disposal of voting securities or voting rights
4) Notification by
	A person that notifies alone
5) Persons subject to the notification requirement
	Name			Address (for legal entifies)
	Atlas Special Opportunities II LLC			2500 Westchester Avenue, Suite 401, Purchase, NY 10577
6) Persons that dispose of votinq rights (only to be filed in it art. 7 of the Law applies)
	Name			Address (for legal entifies)
B	Please continue entering the information in part if concerning the persons referred to In Sections 5 and 6			Part II
7) Date on which the threshold is crossed
		26/05/2025 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
		10
	If the holding has fallen below the lowest threehold, you have the option of not entering any numbers in Section 10
9) Denominator
		8,496,303
	Please enter the denominator before filling in the data
10) Notified details
A) Voling rights	Previous notification			After the transaction
	# of voting rights			# of voting rights		% of voting rights
Holders of voting rights			Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Atlas Special Opportunities II LLC	1,222,807		621,773

+

Start with "groups" of holders. Add eutotals with 2, , and then finish with the parons who are "alone".
For groups, start with the uitimate controlling natural person or lega

621,773

.

7.32%

0.00%

TOTAL

B) Equivalent financial Instruments	After the transaction
Holders of equivalent financial instruments	Type of financial Instrument	Expiration date	Exercise period or diste	# of voting rights that may be acquired if the Instrument Is exercised	% of voting rights	Settlement
							+
	TOTAL			0	0.00%
	The reesle will be undered ange you hous alloked on JOALOUI ATCs.

The zorals will be updated once you have cilcked on

TOTAL (A & B)			# of voting rights = % of voting rights
	CALCULATE	621,773	7.32%

11) Full chain of controlled undertakings through which the holding is effectively held, it applicable

Atlas Special Opportunities II LLC is not a controlled entity.

12) In case of proxy votinq for only one GM

Holder	will cease to hold / will hold again	voting rights as of	Continued a le a le f

13) Additional information

On 1 a reality and the manages and special copedialles i LC ocles (2010). M., a a result in this is canading desease b (2220) alser - 1.3%)
chiniater - 1,3% (4 meterneri che

Done at New York
On	25/06/2025 (DD/MMYYYYY)
Name & capacity Patrick Vance, Proxyholder	Signature

For security reasons, the unsigned form in xlsx format should
be transmitted to trp.fin@tsma.be. You can do this manually
OR if you have MS Outlook at your disposal via the "

In addition, a signed copy in EDE format should also be
transmitted.